Antony Currie and Robert Cyran discuss how Valeant's possible increased bid, the potential return of Actavis as a suitor and a looming vote deadline should finally decide Allergan's fate.
01:41
00:59
01:25
02:04
00:29
02:03
01:12
01:15
01:30
02:37
02:11
00:40
02:29
00:42
00:40
00:41
01:01
00:57
00:31
01:23
02:29
00:57
02:22
00:47
01:22
01:08
01:01
02:59
01:49
00:49
02:23
00:50
02:26
01:53
00:45
01:09
00:55
01:27
00:49
00:45
01:15
01:30
02:37
00:40
00:40
00:30
01:15
00:17
02:26
00:47
00:28
00:52
00:33
01:05
00:25
01:59
01:34
00:33
00:40
00:28
01:46
01:23
01:07
00:55
01:41
01:04
02:26
03:03
02:30
01:49
02:14
01:27
02:03
01:21
07:58
00:29
01:08
01:21
01:15
02:33
01:02
01:28
01:57
01:03
02:00
03:34
01:30
00:51
02:02
00:51
02:07
02:05
01:36
01:23
02:26
01:11
00:28
01:38
01:00
01:23
01:18
01:09
01:23
01:26
01:35
01:07
02:52
05:07
01:11
01:42
01:55
01:29
00:59
00:49
00:57
01:41
02:09
01:36
00:48
01:00